Talis Biomedical (TLIS) Competitors

Astrotech (NASDAQ:ASTC) and Talis Biomedical (NASDAQ:TLIS) are both small-cap aerospace companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, media sentiment, dividends, valuation, community ranking, analyst recommendations, risk and earnings.

Do institutionals & insiders believe in ASTC or TLIS?

24.4% of Astrotech shares are held by institutional investors. Comparatively, 43.8% of Talis Biomedical shares are held by institutional investors. 14.9% of Astrotech shares are held by insiders. Comparatively, 46.0% of Talis Biomedical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Does the media favor ASTC or TLIS?

In the previous week, Astrotech had 1 more articles in the media than Talis Biomedical. MarketBeat recorded 1 mentions for Astrotech and 0 mentions for Talis Biomedical. Astrotech's average media sentiment score of 0.97 beat Talis Biomedical's score of 0.00 indicating that Astrotech is being referred to more favorably in the media.

Company	Overall Sentiment
Astrotech	Positive
Talis Biomedical	Neutral

Which has stronger valuation and earnings, ASTC or TLIS?

Astrotech has higher earnings, but lower revenue than Talis Biomedical. Astrotech is trading at a lower price-to-earnings ratio than Talis Biomedical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Astrotech	$1.66M	6.82	-$11.67M	-$7.34	-0.91
Talis Biomedical	$2.13M	1.34	-$62.01M	-$28.02	-0.06

Which has more volatility and risk, ASTC or TLIS?

Astrotech has a beta of -0.17, suggesting that its share price is 117% less volatile than the S&P 500. Comparatively, Talis Biomedical has a beta of 1.52, suggesting that its share price is 52% more volatile than the S&P 500.

Is ASTC or TLIS more profitable?

Talis Biomedical has a net margin of 0.00% compared to Astrotech's net margin of -945.17%. Astrotech's return on equity of -33.26% beat Talis Biomedical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Astrotech	-945.17%	-33.26%	-31.03%
Talis Biomedical	N/A	-79.74%	-57.16%

Does the MarketBeat Community favor ASTC or TLIS?

Astrotech received 119 more outperform votes than Talis Biomedical when rated by MarketBeat users. Likewise, 56.64% of users gave Astrotech an outperform vote while only 37.50% of users gave Talis Biomedical an outperform vote.

Company	Underperform	Outperform
Astrotech	Outperform Votes 128 56.64%	Underperform Votes 98 43.36%
Talis Biomedical	Outperform Votes 9 37.50%	Underperform Votes 15 62.50%

Summary

Astrotech beats Talis Biomedical on 9 of the 15 factors compared between the two stocks.